
## Benedetto Farsaci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1569156/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncology, The, 2016, 17, 1283-1294.	5.1	818
2	Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. Journal of Clinical Oncology, 2018, 36, 1428-1439.	0.8	551
3	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. Journal of Clinical Oncology, 2018, 36, 942-950.	0.8	273
4	Chemotherapyâ€induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. International Journal of Cancer, 2013, 133, 624-636.	2.3	225
5	Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncolmmunology, 2013, 2, e27025.	2.1	148
6	The Tipping Point for Combination Therapy: Cancer Vaccines With Radiation, Chemotherapy, or Targeted Small Molecule Inhibitors. Seminars in Oncology, 2012, 39, 323-339.	0.8	132
7	Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. International Journal of Cancer, 2012, 130, 1948-1959.	2.3	115
8	Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer. Cancer Immunology Research, 2014, 2, 133-141.	1.6	115
9	A Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 039). Blood, 2016, 128, 183-183.	0.6	107
10	Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer. JAMA Oncology, 2015, 1, 1087.	3.4	80
11	Combination Therapy with a Second-Generation Androgen Receptor Antagonist and a Metastasis Vaccine Improves Survival in a Spontaneous Prostate Cancer Model. Clinical Cancer Research, 2013, 19, 6205-6218.	3.2	75
12	Therapeutic Cancer Vaccines. Advances in Cancer Research, 2014, 121, 67-124.	1.9	68
13	Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines. Cancer Immunology Research, 2014, 2, 1090-1102.	1.6	62
14	Adverse events after infusions of cryopreserved hematopoietic stem cells depend on non-mononuclear cells in the infused suspension and patient age. Cytotherapy, 2007, 9, 348-355.	0.3	50
15	Effect of a small molecule BCLâ $\in 2$ inhibitor on immune function and use with a recombinant vaccine. International Journal of Cancer, 2010, 127, 1603-1613.	2.3	41
16	Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. Cancer Immunology Research, 2016, 4, 755-765.	1.6	36
17	TGF-β modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression. Cancer Immunology, Immunotherapy, 2009, 58, 1809-1818.	2.0	26
18	Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclax), Decreases Human T Regulatory Lymphocytes while Preserving Effector T Lymphocytes: A Rationale for Its Use in Combination Immunotherapy. Journal of Immunology, 2014, 192, 2622-2633.	0.4	25

Benedetto Farsaci

#	Article	IF	CITATIONS
19	Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack. , 2015, 3, 52.		22
20	Distinct Effects of Saracatinib on Memory CD8+ T Cell Differentiation. Journal of Immunology, 2012, 188, 4323-4333.	0.4	15
21	PD-L1 and MHC-I expression in 19 human tumor cell lines and modulation by interferon-gamma treatment. , 2014, 2, .		15
22	An alternative dielectric model for low and high frequencies: A non-equilibrium thermodynamic approach. Journal of Non-Equilibrium Thermodynamics, 2012, 37, .	2.4	11
23	1370: Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profling analyses. Journal of Thoracic Oncology, 2016, 11, S115-S116.	0.5	10
24	CD34+ selected haematopoietic stem cell (HSC) not preceded by any immunosuppressive therapy as effective treatment for graft failure. Bone Marrow Transplantation, 2005, 35, 521-522.	1.3	8
25	Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)—A phase 2 study Journal of Clinical Oncology, 2016, 34, 7535-7535.	0.8	8
26	NCI experience using yeast-brachyury vaccine (GI-6301) in patients (pts) with advanced chordoma Journal of Clinical Oncology, 2014, 32, 3081-3081.	0.8	6
27	Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets. International Journal of Cancer, 2014, 135, 862-870.	2.3	5
28	Chromosome 9p24.1/PD-L1/PD-L2Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade). Blood, 2016, 128, 2923-2923.	0.6	5
29	Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301). , 2014, 2, .		3
30	PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients. , 2014, 2, .		2
31	Abstract 4790: Docetaxel modulates phenotype of human carcinoma cells, including drug-resistant tumor cells, resulting in enhanced killing by CTLs. , 2010, , .		2
32	Nivolumab in combination with daratumumab, with or without pomalidomide and dexamethasone, for relapsed/refractory multiple myeloma: 2 cohorts of the phase 1 CheckMate 039 safety study Journal of Clinical Oncology, 2017, 35, TPS3102-TPS3102.	0.8	2
33	Recombinant TRICOM-based Therapeutic Cancer Vaccines. , 2013, , 309-331.		1
34	Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. , 2013, 1, .		1
35	Digital immunohistochemistry analysis of intratumoral immune infiltrates in prostate cancer patients treated with intraprostatic/systemic PSA-TRICOM vaccine. , 2013, 1, .		1
36	Design, development, and translation of poxvirus-based vaccines for cancer. , 2011, , 56-77.		1

36 Design, development, and translation of poxvirus-based vaccines for cancer., 2011,, 56-77.

#	Article	IF	CITATIONS
37	Abstract 1316: Evaluation of immune cell subsets of cancer patients treated with a fully human IgG1 anti-PD-L1 MAb (MSB0010718C) capable of mediating ADCC of human tumor cells. Cancer Research, 2015, 75, 1316-1316.	0.4	1
38	Abstract CT225: A Phase Ib/IIa randomized pilot study to investigate the safety and tolerability of autologous T-cells with enhanced T-cell receptors specific to NY-ESO-1/LAGE-1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer. , 2019, , .		1
39	Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival. , 2013, 1, .		Ο
40	Effects of tyrosine kinase inhibitors alone or in combination with vaccine on tumor-infiltrating myeloid cells. , 2013, 1, .		0
41	Tumor vascular normalization as a strategy to potentiate effectiveness of therapeutic vaccines. , 2014, 2, .		Ο
42	Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study. Annals of Oncology, 2019, 30, v657-v658.	0.6	0
43	Adverse Events after Infusions of Cryopreserved Hematopoietic Stem Cells Depend on Non-Mononuclear Cell in Infused Suspension and on Patient Age Blood, 2006, 108, 5244-5244.	0.6	0
44	Failure of CD34+ Mobilization in AML Patients Is Associated to an Abnormally High Chemosensitivity of Non Leukemic CFU-GM Blood, 2007, 110, 2849-2849.	0.6	0
45	Abstract 3979: In vitro analysis of pan-BCL-2 inhibitor GX15-070 (obatoclax) on human lymphocytes for the feasibility of combination immunotherapy , 2013, , .		0
46	Abstract 1676: Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death , 2013, , .		0
47	Abstract 1232: Immunomodulatory effects of a tyrosine kinase inhibitor and vascular remodeling properties of a cancer vaccine potentiate combinatorial immunotherapy , 2013, , .		Ο
48	Abstract 2544: Identification of immune signatures predicting for clinical outcome measured by flow-cytometry and immunogenetic analysis of PBMCs from breast cancer patients treated with docetaxel alone or docetaxel plus vaccine. , 2014, , .		0
49	Abstract 628: Pan-Bcl-2 inhibitor, GX15-070 (Obatoclax), decreases human T regulatory lymphocytes while preserving effector T Lymphocytes: A rationale for its use in combination immunotherapy. , 2014, , .		0
50	Abstract LB-072: Impact of baseline serum cytokines on survival in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC) treated with nivolumab (nivo) or docetaxel (doc): Exploratory analyses from CheckMate 063 and CheckMate 017. , 2016, , .		0